Mpox (monkeypox) vaccine safety surveillance Our work Main navigation National vaccine safety surveillance Active vaccine safety surveillance Mpox (monkeypox) vaccine safety surveillance COVID-19 vaccine safety surveillance Adverse event of special interest (AESI) long-term follow-up program Adverse Events Following Immunisation Clinical Assessment Network (AEFI-CAN) Vaccine safety in Australia AusVaxSafety summary report Publications AusVaxSafety is actively monitoring adverse events following mpox (monkeypox) vaccination to ensure continuing safety of vaccines used. How to get involved? If you are getting a mpox vaccine, look out for the AusVaxSafety QR code registration poster at your immunisation clinic. Scan the QR code and complete the registration form to participate in the AusVaxSafety mpox vaccine surveillance program. How does it work? Following your mpox vaccination, AusVaxSafety will send you three short vaccine safety surveys - on day 7, day 14 and day 42 - giving you the opportunity to report any adverse events you may have experienced and if you had to seek medical care as a result. Depending on your survey responses, your state/territory health department or immunisation provider may contact you to collect more details. What happens to the information you provide? Your responses will contribute to the national mpox vaccine safety surveillance that AusVaxSafety is conducting as part of Australia's comprehensive vaccine safety monitoring. What about your personal data? AusVaxSafety only receives responses that are de-identified to protect your privacy. This means any information that could identify you will be removed. More information If you have any questions or would like more information on the AusVaxSafety mpox vaccine safety surveillance program, contact the AusVaxSafety team. View the latest AusVaxSafety mpox vaccine safety data here Our work Main navigation National vaccine safety surveillance Active vaccine safety surveillance Mpox (monkeypox) vaccine safety surveillance COVID-19 vaccine safety surveillance Adverse event of special interest (AESI) long-term follow-up program Adverse Events Following Immunisation Clinical Assessment Network (AEFI-CAN) Vaccine safety in Australia AusVaxSafety summary report Publications News & events All news & events 17 May 2023 | News Subcutaneous and intradermal administration of mpox vaccine well tolerated, AusVaxSafety study finds 10 May 2023 | News New bivalent BA.4/BA.5 COVID-19 booster vaccines well tolerated by Australians, new AusVaxSafety data show 20 April 2023 | News Influenza is back in Australia in 2023: Why a flu shot is so important, who is eligible and what to expect in the days following your vaccination 04 April 2023 | News AusVaxSafety commences routine surveillance of 2023 seasonal flu vaccines